A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers
NCT ID: NCT04683484
Last Updated: 2020-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
620 participants
INTERVENTIONAL
2020-12-10
2021-08-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The clinical trial Phase 2, randomization, double-blind, multicenter, placebo-controlled to evaluate the safety, immunogenicity, and determined the optimal dose of the Vaccine Nanocovax intramuscularly in healthy volunteers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose of Nanocovax
Intramuscular injection, two doses given 28 days apart
Nanocovax
Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
Middle dose of Nanocovax
Intramuscular injection, two doses given 28 days apart
Nanocovax
Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
High dose of Nanocovax
Intramuscular injection, two doses given 28 days apart
Nanocovax
Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
Placebo
Intramuscular injection, two doses given 28 days apart
Placebo
0,5 mg Al PO4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nanocovax
Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
Placebo
0,5 mg Al PO4
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) between 18 and 28 kg/m2
* The subject has good health, is assessed through medical history, clinical examination, and laboratory tests (such as hematology, biochemistry, urine ...) within the normal range evaluated by the clinician.
* Subjects aged potentially pregnant should use effective contraceptive methods 4 weeks prior to screening and during the study and last until 6 months after the last injection.
* Able and willing to participate in all activities in the clinical trial, including 6-month follow-up after vaccination.
* Sign the consent form. For a subject from 12 to 17 years old, it is necessary to have a legal guardian sign the consent form to participate in the study
Exclusion Criteria
* Subjects at high risk of SARS-CoV-2 infection.
* Subject is/has ever had any acute or chronic medical condition, including but not limited to:
* Have any inflammatory disease, respiratory tract infection, have any respiratory symptoms such as: cough, sore throat, difficulty breathing, wheezing due to respiratory symptoms within 07 days before screening. Fever (armpit temperature ≥ 37°C) for 3 days before vaccination.
* History of any chronic respiratory illness such as bronchial asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease (COPD).
* Malignant disease
* Immune disorders, using immunosuppressive therapy.
* Cardiovascular diseases (including high blood pressure requiring drug treatment), liver disease, chronic kidney disease, endocrine diseases (including diabetes), hemoglobin disease ...
* Neurological, psychiatric, epilepsy, or Guillian-Barré disorders.
* Pathology of hemostasis.
* Having any surgery for 8 weeks before screening.
* History of organ transplantation.
* Examination and testing results at the time of screening:
* Systolic pressure above 140 mmHg and/or diastolic pressure over 90mmHg;
* Systolic blood pressure less than 90 mmHg and/or diastolic pressure below 50 mmHg
* Real-Time nasopharyngeal fluid test - PCR (positive) and/or anti S - IgG (positive) with SARS-CoV-2.
* Women of potential pregnancy, a positive urine beta-hCG test at the time of screening.
* Positive with HIV, hepatitis B (HBsAg), hepatitis C (ANTI-HCV) tests
* WBC less than 3.5 x 10\^9 cells / L
* Lymphocytes of less than 1.0 x 10\^9 cells / L.
* Neutrophils less than 2.0 x 10\^9 cells / L
* Platelets below 140 x 10\^9 cells / l
* Hb less than 120 g/L for men and less than 100 g/L for women
* ALT or AST is over 2 times the normal limit
* eGFR of 90 mL/min/ 1.73m2 or less.
* Abnormal ECG of clinical significance.
* The Subject who have taken any drugs or treatments simultaneously and before:
* Any drug or treatment that affects the immune system such as injectable anti-allergenic drugs, Globulin, Interferon, immunomodulators, cytotoxic drugs, or any other drug toxic to the body, for 90 days before screening.
* Systemic steroids (oral or injectable; including intra-articular injection) regardless of dose except for topical form, for 28 days prior to screening.
* Any vaccine within 28 days prior to screening or planned for in-study vaccination or after 6 months after the first vaccination.
* Receive or donate blood/serum during the 8 weeks prior to the screening, or plan to receive or donate blood/serum during the study period.
* The Subject that participated in any clinical trial 28 days prior to the screening date or intends to participate in another clinical study at any point in the study.
* Women who are pregnant and breastfeeding or planning to become pregnant for the next 6 months from the time of the study 2 vaccines.
* The Subject has a history of allergy to any of the vaccine components understudying or has a history of at least one past history of allergic or hypersensitivity reactions.
* The Subject addicted to alcohol (drinking from 5 cups of alcohol daily, glasses of alcohol/can of beer), tobacco/water pipe addicts (smoking from 5 or more cigarettes), drug addiction, opioid dependence
* The Subject is a member of the research team, sponsor employee, producer (Nanogen), and a person related by family (wife, husband, child, father, mother) with those subjects.
12 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Military Medical Academy
Hanoi, Ha Dong, Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Men chu, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Nguyen TP, Do Q, Phan LT, Dinh DV, Khong H, Hoang LV, Nguyen TV, Pham HN, Chu MV, Nguyen TT, Pham QD, Le TM, Trang TNT, Dinh TT, Vo TV, Vu TT, Nguyen QBP, Phan VT, Nguyen LV, Nguyen GT, Tran PM, Nghiem TD, Tran TV, Nguyen TG, Tran TQ, Nguyen LT, Do AT, Nguyen DD, Ho SA, Nguyen VT, Pham DT, Tran HB, Vu ST, Hoang SX, Do TM, Nguyen XT, Le GQ, Tran T, Cao TM, Dao HM, Nguyen TTT, Doan UY, Le VTT, Tran LP, Nguyen NM, Nguyen NT, Pham HTT, Nguyen QH, Nguyen HT, Nguyen HLK, Tran VT, Tran MTN, Nguyen TTT, Ha PT, Huynh HT, Nguyen KD, Thuan UT, Doan CC, Do SM. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. Lancet Reg Health West Pac. 2022 May 16;24:100474. doi: 10.1016/j.lanwpc.2022.100474. eCollection 2022 Jul.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNG26
Identifier Type: -
Identifier Source: org_study_id